Orthotopic and Bioluminescent Models

• Amenable to large scale studies and high throughput 
• Fast and efficient 2D imaging (3-5 animals at a time)
• Simplified positive randomization and optimal treatment initiation on established tumors across all groups
• Cost effective platform - reducing animal number per study and providing more data from each animal

Our cutting edge imaging techniques and platforms include:

• 2D bioluminescence, multispectral fluorescence, and spectral unmixing
• 3D optical tomography (IVIS^® Spectrum)
• Low dose and ultra-fast microCT (IVIS Spectrum/CT)
• DyCE™ dynamic contrast enhanced imaging for real time distribution studies

Our panel of orthotopic bioluminescent models include syngeneic as well as xenograft lines.

• Choose orthotopic bioluminescent models to monitor your compound antitumor activity in real time using bioluminescent imaging, in the presence of a relevant TME.
  
  
• Choose bioluminescent experimental metastasis models to mimic hard to develop late-stage disease, such as bone or brain metastases, and obtain patient-relevant information on the metastatic niche. These models are established by seeding bioluminescent tumor cells either i.v. to facilitate lodging at the metastatic site, or directly into the organ where clinical metastases have been seen.
  
  
• Choose bioluminescent systemic models for an easier monitoring of tumor burden and response to treatment in absence of palpable solid tumors via real time longitudinal imaging.

Table 1: Available bioluminescent models (additional models under development and can be developed upon client request)

Orthotopic Models

Systemic Models

Experimental Metastasis Models

*Client license required
Models provided by sponsor but the right of use has been granted (not fit for CFDA studies)